Recombinant cxcl1

Manufactured by Thermo Fisher Scientific

Recombinant CXCL1 is a protein produced using recombinant DNA technology. It is a member of the CXC chemokine family and is involved in the regulation of inflammatory processes.

Automatically generated - may contain errors

Lab products found in correlation

Mk 2206 2hci, by Selleck Chemicals (1 mentions) Sb225002, by Selleck Chemicals (1 mentions) Jsh 23, by Selleck Chemicals (1 mentions) Recombinant tgf β1, by R&D Systems (1 mentions) Sb505124, by Selleck Chemicals (1 mentions) Tnf α, by Thermo Fisher Scientific (1 mentions) Cxcl2, by Thermo Fisher Scientific (1 mentions) Transwell insert, by Corning (1 mentions)

Close spelling variants of this product

CXCL1 (75 citations) Recombinant human CXCL1 (5 citations) Recombinant murine CXCL1 (4 citations) Recombinant human CXCL1-3 (3 citations) Recombinant rat CXCL1 (2 citations) Recombinant mouse CXCL1 (2 citations)

3 protocols using recombinant cxcl1

Modulating TGFβ and NF-κB Signaling in Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

For the treatment of KYSE30 and KYSE450 cells, recombinant TGFβ1 (R&D, Minneapolis, MN, USA) was used at a final concentration of 10 ng·mL⁻¹ unless otherwise specified. TNFα (PeproTech, Suzhou, China) was used at a final concentration of 10 ng·mL⁻¹. Treatment periods were 24 h unless otherwise specified. We used 10 μm SB505124 and 10 μm JSH‐23 (Selleck, Houston, TX, USA) to inhibit TGFβ signaling and NF‐κB signaling, respectively. These inhibitors were administered to the cells 30 min before any other treatments. In addition, 5 µm MK‐2206 2HCI (Selleck) was used to inhibit Akt phosphorylation selectively for 24 h. CAF were treated with 10 ng·mL⁻¹ recombinant CXCL1 (PeproTech) for 24 h. SB225002 (Selleck) was added 1 h prior to inhibiting CXCL1/CXCR2.

Fang L., Che Y., Zhang C., Huang J., Lei Y., Lu Z., Sun N, & He J. (2021). LAMC1 upregulation via TGFβ induces inflammatory cancer‐associated fibroblasts in esophageal squamous cell carcinoma via NF‐κB–CXCL1–STAT3. Molecular Oncology, 15(11), 3125-3146.

+ Open protocol

+ Expand

CXCL1 Administration in Lean Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Recombinant CXCL1 (Peprotech, #250‐11) or vehicle (PBS) was administered to lean C57BL/6 via i.p. injection (5 mg/kg in PBS) daily for 7 days.

Lagnado A., Leslie J., Ruchaud‐Sparagano M., Victorelli S., Hirsova P., Ogrodnik M., Collins A.L., Vizioli M.G., Habiballa L., Saretzki G., Evans S.A., Salmonowicz H., Hruby A., Geh D., Pavelko K.D., Dolan D., Reeves H.L., Grellscheid S., Wilson C.H., Pandanaboyana S., Doolittle M., von Zglinicki T., Oakley F., Gallage S., Wilson C.L., Birch J., Carroll B., Chapman J., Heikenwalder M., Neretti N., Khosla S., Masuda C.A., Tchkonia T., Kirkland J.L., Jurk D., Mann D.A, & Passos J.F. (2021). Neutrophils induce paracrine telomere dysfunction and senescence in ROS‐dependent manner. The EMBO Journal, 40(9), e106048.

+ Open protocol

+ Expand

Neutrophil Chemotaxis Assay with CXCL1/2

Check if the same lab product or an alternative is used in the 5 most similar protocols

Chemotaxis assay was performed using 24-well plates with 6.5-mm (3 μm pore size) Transwell inserts (Corning Costar, Tewksbury, MA). After FACS purification, neutrophils were suspended in complete RPMI medium at a density of 1 × 10⁷ cells/ml and added to the upper chamber (100 μl/well). Complete RPMI containing 30 nM of recombinant CXCL1 and/or CXCL2 (both from PeproTech, Rocky Hill, NJ) was added to the lower chamber (600 μl/well). After 2 h incubation at 37°C, “migrated” cells were harvested from the lower chambers. The cells remaining in the upper chambers were harvested as “unmigrated” cells. The samples were examined for cell numbers and viability by FACS, and the level of migration (% migration) was then calculated by dividing the number of migrated cells by the total cell numbers recovered from the well (i.e., migrated cells plus unmigrated cells).

Yao Y., Matsushima H., Ohtola J.A., Geng S., Lu R, & Takashima A. (2014). Neutrophil priming occurs in a sequential manner and can be visualized in living animals by monitoring IL-1β promoter activation. Journal of immunology (Baltimore, Md. : 1950), 194(3), 1211-1224.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!